A BODIPY-based fluorescent sensor for the detection of Pt2+ and Pt drugs.

A BODIPY-based fluorescent sensor PS with an NO4S2 podand ligand was studied for the selective detection of Pt2+ over 21 cations as well as selected platinum drugs in aqueous medium. The platinum sensor PS shows 28-fold, 22-fold and 14-fold fluorescence turn-on enhancements to Pt2+, cisplatin and nedaplatin, and was thereby employed to detect platinum drugs in A-549 human lung cancer cells.

[1]  W. Ang,et al.  A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes. , 2018, Angewandte Chemie.

[2]  S. Stürup,et al.  Development and validation of an ICP‐MS method for quantification of total carbon and platinum in cell samples and comparison of open‐vessel and microwave‐assisted acid digestion methods , 2018, Journal of pharmaceutical and biomedical analysis.

[3]  You-nian Liu,et al.  Mitochondria-targeted platinum(II) complexes induce apoptosis-dependent autophagic cell death mediated by ER-stress in A549 cancer cells. , 2018, European journal of medicinal chemistry.

[4]  Xiaohe Liu,et al.  Sequential recognition of Hg2+ and I− based on a novel BODIPY-salen sensor , 2017 .

[5]  A. Ciavardini,et al.  Cisplatin and transplatin interaction with methionine: bonding motifs assayed by vibrational spectroscopy in the isolated ionic complexes. , 2017, Physical chemistry chemical physics : PCCP.

[6]  O. Kanat,et al.  Platinum-induced neurotoxicity: A review of possible mechanisms , 2017, World journal of clinical oncology.

[7]  Junchen Wu,et al.  An effective peptide cargo carrier for the delivery of cisplatin in ovarian cancer cells , 2017 .

[8]  M. Michaelis,et al.  Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest , 2017, PloS one.

[9]  Wei Huang,et al.  Self-assembled nanoparticles based on a cationic conjugated polymer/hyaluronan–cisplatin complex as a multifunctional platform for simultaneous tumor-targeting cell imaging and drug delivery , 2017 .

[10]  René M. Botnar,et al.  Gadolinium and Platinum in Tandem: Real-time Multi-Modal Monitoring of Drug Delivery by MRI and Fluorescence Imaging , 2017, Nanotheranostics.

[11]  D. Buccella,et al.  Bright, red emitting fluorescent sensor for intracellular imaging of Mg2+ . , 2016, Organic & biomolecular chemistry.

[12]  I. Klimant,et al.  Red‐ to NIR‐Emitting, BODIPY‐Based, K+‐Selective Fluoroionophores and Sensing Materials , 2016 .

[13]  Cheuk‐Lam Ho,et al.  Elemental bioimaging of platinum in mouse tissues by laser ablation-inductively coupled plasma-mass spectrometry for the study of localization behavior of structurally similar complexes , 2016 .

[14]  Siling Wang,et al.  Cisplatin Prodrug-Conjugated Gold Nanocluster for Fluorescence Imaging and Targeted Therapy of the Breast Cancer , 2016, Theranostics.

[15]  C. S. Allardyce,et al.  Metal-based drugs that break the rules. , 2016, Dalton transactions.

[16]  S. Lippard,et al.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. , 2016, Chemical reviews.

[17]  V. Brabec,et al.  Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc04205d , 2016, Chemical science.

[18]  S. Yap,et al.  Structure-activity relationship studies on rhodamine B-based fluorogenic probes and their activation by anticancer platinum(II) compounds. , 2015, Journal of inorganic biochemistry.

[19]  Aurora L. Ginzburg,et al.  Azide vs Alkyne Functionalization in Pt(II) Complexes for Post-treatment Click Modification: Solid-State Structure, Fluorescent Labeling, and Cellular Fate. , 2015, Journal of the American Chemical Society.

[20]  M. Hemann,et al.  A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. , 2015, Journal of the American Chemical Society.

[21]  P. Steyger,et al.  An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. , 2015, Toxicology letters.

[22]  T. Hambley,et al.  Fluorescent sensing of monofunctional platinum species. , 2015, Chemical communications.

[23]  Bosung Kim,et al.  Novel BODIPY-based fluorescence turn-on sensor for Fe3+ and its bioimaging application in living cells. , 2014, ACS applied materials & interfaces.

[24]  D. Osella,et al.  Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one. , 2014, Dalton transactions.

[25]  A. Schintlmeister,et al.  NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs , 2014, Chemical science.

[26]  S. Yap,et al.  A fluorescent probe for investigating the activation of anticancer platinum(IV) prodrugs based on the cisplatin scaffold. , 2013, Angewandte Chemie.

[27]  J. Kigawa,et al.  Nedaplatin: a cisplatin derivative in cancer chemotherapy , 2013, Cancer management and research.

[28]  D. Raible,et al.  Functional Mechanotransduction Is Required for Cisplatin-Induced Hair Cell Death in the Zebrafish Lateral Line , 2013, The Journal of Neuroscience.

[29]  Xiangge Zhou,et al.  Simple, selective, and sensitive colorimetric and ratiometric fluorescence/phosphorescence probes for platinum(II) based on Salen-type Schiff bases , 2012 .

[30]  G. Pastorin,et al.  Platinum(IV) prodrugs entrapped within multiwalled carbon nanotubes: Selective release by chemical reduction and hydrophobicity reversal , 2012 .

[31]  J. Tae,et al.  Rhodamine triazole-based fluorescent probe for the detection of Pt(2+). , 2010, Organic letters.

[32]  G. Ramesh,et al.  Mechanisms of Cisplatin Nephrotoxicity , 2010, Toxins.

[33]  B. Michalke.  Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs. , 2010, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[34]  Sheel C. Dodani,et al.  A turn-on fluorescent sensor for detecting nickel in living cells. , 2009, Journal of the American Chemical Society.

[35]  T. Soldatović,et al.  Influence of the chloride concentration on ligand substitution reactions of [Pt(SMC)Cl(2)] with biologically relevant nucleophiles. , 2009, Dalton transactions.

[36]  T. Hambley,et al.  Investigations using fluorescent ligands to monitor platinum(IV) reduction and platinum(II) reactions in cancer cells. , 2009, Dalton transactions.

[37]  Fathi Zereini,et al.  Airborne particulate matter, platinum group elements and human health: a review of recent evidence. , 2009, The Science of the total environment.

[38]  J. States,et al.  Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role , 2009, Journal of ovarian research.

[39]  K. Koide,et al.  Studies of a fluorogenic probe for palladium and platinum leading to a palladium-specific detection method. , 2009, Chemical communications.

[40]  K. Koide,et al.  Fluorescent method for platinum detection in buffers and serums for cancer medicine and occupational hazards. , 2009, Chemical communications.

[41]  G. Natile,et al.  Interaction between platinum complexes and a methionine motif found in copper transport proteins. , 2007, Angewandte Chemie.

[42]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[43]  T. Soldatović,et al.  Study of the reactions between platinum(II) complexes and L-methionine in the presence and absence of 5'-GMP. , 2005, Journal of inorganic biochemistry.

[44]  G. Samimi,et al.  Confocal Microscopic Analysis of the Interaction between Cisplatin and the Copper Transporter ATP7B in Human Ovarian Carcinoma Cells , 2004, Clinical Cancer Research.

[45]  Jan Reedijk,et al.  New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Fuertes,et al.  Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. , 2003, Chemical reviews.

[47]  S. Mcdougall,et al.  Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. , 2000, Journal of pharmaceutical and biomedical analysis.

[48]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[49]  S. Lippard,et al.  Understanding and improving platinum anticancer drugs--phenanthriplatin. , 2014, Anticancer research.

[50]  J. Reedijk.  Metal-Ligand Exchange Kinetics in Platinum and Ruthenium Complexes , 2008 .

[51]  H. Niitani,et al.  Cisplatin/carboplatin therapy in non-small cell lung cancer. , 1992, Oncology.